Compare Dr. Reddys with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SUN PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SUN PHARMA DR. REDDYS LAB/
SUN PHARMA
 
P/E (TTM) x 17.4 20.9 83.0% View Chart
P/BV x 3.3 2.5 135.8% View Chart
Dividend Yield % 0.7 0.7 108.9%  

Financials

 DR. REDDYS LAB   SUN PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
SUN PHARMA
Mar-19
DR. REDDYS LAB/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875679 423.5%   
Low Rs1,888375 502.9%   
Sales per share (Unadj.) Rs930.2121.1 767.9%  
Earnings per share (Unadj.) Rs117.413.4 877.8%  
Cash flow per share (Unadj.) Rs185.820.7 898.1%  
Dividends per share (Unadj.) Rs20.002.75 727.3%  
Dividend yield (eoy) %0.80.5 161.0%  
Book value per share (Unadj.) Rs844.4172.6 489.3%  
Shares outstanding (eoy) m166.072,399.26 6.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.4 58.8%   
Avg P/E ratio x20.339.4 51.5%  
P/CF ratio (eoy) x12.825.5 50.3%  
Price / Book Value ratio x2.83.1 92.3%  
Dividend payout %17.020.6 82.8%   
Avg Mkt Cap Rs m395,4961,264,650 31.3%   
No. of employees `00022.017.5 125.5%   
Total wages/salary Rs m33,56259,671 56.2%   
Avg. sales/employee Rs Th7,032.816,608.1 42.3%   
Avg. wages/employee Rs Th1,527.93,409.6 44.8%   
Avg. net profit/employee Rs Th887.71,833.8 48.4%   
INCOME DATA
Net Sales Rs m154,482290,659 53.1%  
Other income Rs m3,37510,255 32.9%   
Total revenues Rs m157,857300,914 52.5%   
Gross profit Rs m31,78263,076 50.4%  
Depreciation Rs m11,34817,533 64.7%   
Interest Rs m8895,553 16.0%   
Profit before tax Rs m22,92050,246 45.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m3,8586,009 64.2%   
Profit after tax Rs m19,50032,093 60.8%  
Gross profit margin %20.621.7 94.8%  
Effective tax rate %16.812.0 140.8%   
Net profit margin %12.611.0 114.3%  
BALANCE SHEET DATA
Current assets Rs m111,101310,692 35.8%   
Current liabilities Rs m58,973173,396 34.0%   
Net working cap to sales %33.747.2 71.4%  
Current ratio x1.91.8 105.1%  
Inventory Days Days7999 80.1%  
Debtors Days Days94112 84.4%  
Net fixed assets Rs m101,245232,477 43.6%   
Share capital Rs m8302,399 34.6%   
"Free" reserves Rs m139,406411,691 33.9%   
Net worth Rs m140,236414,091 33.9%   
Long term debt Rs m22,00015,226 144.5%   
Total assets Rs m224,656646,938 34.7%  
Interest coverage x26.810.0 266.5%   
Debt to equity ratio x0.20 426.6%  
Sales to assets ratio x0.70.4 153.1%   
Return on assets %9.15.8 156.0%  
Return on equity %13.97.8 179.4%  
Return on capital %14.910.2 147.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67366,025 134.3%   
Fx outflow Rs m19,10438,610 49.5%   
Net fx Rs m69,56927,415 253.8%   
CASH FLOW
From Operations Rs m28,70421,965 130.7%  
From Investments Rs m-7,727-6,813 113.4%  
From Financial Activity Rs m-21,326-27,305 78.1%  
Net Cashflow Rs m-314-8,442 3.7%  

Share Holding

Indian Promoters % 25.5 63.7 40.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 5.1 105.3%  
FIIs % 35.3 23.0 153.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.3 184.3%  
Shareholders   75,885 133,026 57.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ABBOTT INDIA  NATCO PHARMA  BIOCON   PFIZER  ALKEM LABORATORIES  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Generate Alpha over the Next Decade(Profit Hunter)

Oct 29, 2019

Here's your chance benefit from a safe approach to making money in stock markets .

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 11, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - AUROBINDO PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS